REGENERON PHARMACEUTICALS (REGN) Stock Analyst Earnings Estimates
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.072B 89.15% | 12.173B -24.26% | 13.117B 7.76% | 14.461B 10.24% | 15.083B 4.30% | 16.086B 6.65% | 17.727B 10.20% | 18.847B 6.32% | 20.163B 6.98% | 20.915B 3.73% | 21.257B 1.64% | |
| EBITDA YoY % growth | 9.233B 142.16% | 5.335B -42.22% | 4.757B -10.85% | 5.538B 16.43% | 5.384B -2.78% | 6.269B 16.44% | 7.129B 13.72% | 7.986B 12.02% | 9.258B 15.93% | 10.03B 8.34% | 10.521B 4.90% | |
| EBIT YoY % growth | 8.947B 150.13% | 4.994B -44.18% | 4.336B -13.19% | 5.326B 22.85% | 5.394B 1.28% | 6.048B 12.12% | 7.357B 21.64% | 8.085B 9.90% | 9.064B 12.11% | 9.696B 6.97% | 10.211B 5.31% | |
| Operating Margin | 55.67% | 41.03% | 33.05% | 36.83% | 35.76% | 37.60% | 41.50% | 42.90% | 44.95% | 46.36% | 48.04% | |
| EPS YoY % growth | 71.38 125.53% | 42.40 -40.60% | 43.78 3.25% | 45.86 4.74% | 45.94 0.18% | 51.67 12.47% | 59.62 15.39% | 65.71 10.22% | 75.45 14.82% | 79.87 5.86% | 82.19 2.91% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 11.30 -4.69% | 11.15 16.79% | 12.64 9.35% | 13.17 5.71% | 11.97 5.88% |
| Revenue Q2Q % growth | 3.828B 11.47% | 3.629B 15.39% | 3.867B 9.02% | 3.979B 6.94% | 4.067B 6.24% |
| EBITDA Q2Q % growth | 1.55B 1.56% | 1.345B 54.14% | 1.692B 27.38% | 1.83B 14.94% | 1.696B 9.42% |
| EBIT Q2Q % growth | 1.39B 25.77% | 1.373B 81.02% | 1.567B 43.30% | 1.647B 33.28% | 1.558B 12.09% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 12.46 7.51% | 11.93 | 0.53 | 4.48% |
| Q2 2024 Q2Q % growth | 11.56 12.89% | 10.83 | 0.73 | 6.79% |
| Q1 2024 Q2Q % growth | 9.55 -5.35% | 10.29 | -0.74 | -7.23% |
| Q4 2023 Q2Q % growth | 11.86 -5.57% | 10.95 | 0.91 | 8.36% |
| Q3 2023 Q2Q % growth | 11.59 4.04% | 10.93 | 0.66 | 6.01% |
| Q2 2023 Q2Q % growth | 10.24 4.81% | 10.04 | 0.20 | 1.99% |
| Q1 2023 Q2Q % growth | 10.09 12.99% | 9.75 | 0.34 | 3.50% |
| Q4 2022 Q2Q % growth | 12.56 -41.09% | 10.23 | 2.33 | 22.77% |
| Q3 2022 Q2Q % growth | 11.14 -22.48% | 9.67 | 1.47 | 15.25% |
| Q2 2022 Q2Q % growth | 9.77 -62.13% | 9.02 | 0.75 | 8.33% |
| Q1 2022 Q2Q % growth | 8.93 -9.71% | 9.93 | -1.00 | -10.09% |
| Q4 2021 Q2Q % growth | 21.32 123.71% | 18.71 | 2.61 | 13.93% |
| Q3 2021 Q2Q % growth | 14.37 71.89% | 10.31 | 4.06 | 39.43% |
| Q2 2021 Q2Q % growth | 25.80 260.34% | 17.88 | 7.92 | 44.32% |
| Q1 2021 Q2Q % growth | 9.89 49.85% | 9.18 | 0.71 | 7.72% |
| Q4 2020 Q2Q % growth | 9.53 27.07% | 8.56 | 0.97 | 11.32% |
| Q3 2020 Q2Q % growth | 8.36 25.34% | 7.28 | 1.08 | 14.87% |
| Q2 2020 Q2Q % growth | 7.16 18.94% | 6.10 | 1.06 | 17.32% |
| Q1 2020 Q2Q % growth | 6.60 48.31% | 6.25 | 0.35 | 5.53% |
| Q4 2019 Q2Q % growth | 7.50 | 7.04 | 0.46 | 6.46% |
| Q3 2019 Q2Q % growth | 6.67 | 6.49 | 0.18 | 2.79% |
| Q2 2019 Q2Q % growth | 6.02 | 5.52 | 0.50 | 9.15% |
| Q1 2019 Q2Q % growth | 4.45 | 5.58 | -1.13 | -20.29% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 3.721B 10.65% | 3.744B | -23.3M | -0.62% |
| Q2 2024 Q2Q % growth | 3.547B 12.32% | 3.446B | 101.1M | 2.93% |
| Q1 2024 Q2Q % growth | 3.145B -0.54% | 3.284B | -139M | -4.23% |
| Q4 2023 Q2Q % growth | 3.434B 0.57% | 3.351B | 83M | 2.48% |
| Q3 2023 Q2Q % growth | 3.363B 14.53% | 3.298B | 64.7M | 1.96% |
| Q2 2023 Q2Q % growth | 3.158B 10.53% | 3.077B | 81.1M | 2.64% |
| Q1 2023 Q2Q % growth | 3.162B 6.64% | 3.06B | 102.1M | 3.34% |
| Q4 2022 Q2Q % growth | 3.414B -31.05% | 3.188B | 226.4M | 7.10% |
| Q3 2022 Q2Q % growth | 2.936B -14.96% | 2.926B | 10.2M | 0.35% |
| Q2 2022 Q2Q % growth | 2.857B -44.40% | 2.852B | 5.2M | 0.18% |
| Q1 2022 Q2Q % growth | 2.965B 17.26% | 2.779B | 186.1M | 6.70% |
| Q4 2021 Q2Q % growth | 4.952B 104.37% | 4.598B | 353.7M | 7.69% |
| Q3 2021 Q2Q % growth | 3.453B 50.51% | 2.873B | 579.8M | 20.18% |
| Q2 2021 Q2Q % growth | 5.139B 163.24% | 3.995B | 1.144B | 28.62% |
| Q1 2021 Q2Q % growth | 2.529B 38.32% | 2.602B | -73.3M | -2.82% |
| Q4 2020 Q2Q % growth | 2.423B 11.68% | 2.471B | -48.1M | -1.95% |
| Q3 2020 Q2Q % growth | 2.294B 31.56% | 2.13B | 164M | 7.70% |
| Q2 2020 Q2Q % growth | 1.952B 23.72% | 1.777B | 175M | 9.85% |
| Q1 2020 Q2Q % growth | 1.828B 33.19% | 1.793B | 35.2M | 1.96% |
| Q4 2019 Q2Q % growth | 2.17B | 2.143B | 26.5M | 1.24% |
| Q3 2019 Q2Q % growth | 1.744B | 2.026B | -282.3M | -13.93% |
| Q2 2019 Q2Q % growth | 1.578B | 1.838B | -260.2M | -14.16% |
| Q1 2019 Q2Q % growth | 1.373B | 1.796B | -423.4M | -23.57% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -8.54% | 0% | -0.21% |
| Revenue | 0% | 0.76% | 0.04% | 0.09% |